Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07413679 · ClinicalTrials.gov registry record
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria and PNH, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07413679 is a study of Paroxysmal Nocturnal Hemoglobinuria and PNH that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 50 participants, below the 261-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07413679, a study of Paroxysmal Nocturnal Hemoglobinuria and PNH, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
Conditions Studied
Interventions
- DRUG Danicopan
Study Locations (1)
Massachusetts
- Alexion Pharmaceuticals, Inc. (Sponsor) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07413679
The ClinicalTrials.gov registry entry for NCT07413679 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (81% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which Danicopan is the first listed.
NCT07413679 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07413679 about?
NCT07413679 is a clinical study titled "Long-term Safety of Danicopan: IPIG Registry-based Cohort Study". This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
What is the current status of trial NCT07413679?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2025-08-18. Estimated completion is 2029-07-01.
What conditions does trial NCT07413679 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH.
What interventions are being tested in trial NCT07413679?
The interventions under investigation include: Danicopan (DRUG).
Who is sponsoring clinical trial NCT07413679?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07413679 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The International PNH Interest Group PNH Registry
RECRUITING
-
Home Reported Outcomes in PNH
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
Global PNH Patient Registry
RECRUITING
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.